Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Humacyte Coronary Tissue Engineered Vessel

Other · developed by Humacyte

Phase 2 Most advanced trial

HUMA Developer

1 Registered trials

What is Humacyte Coronary Tissue Engineered Vessel?

Humacyte Coronary Tissue Engineered Vessel (CTEV) is an acellular vascular conduit with an inner diameter of 3.5 mm and approximately 20 cm of usable length. It is being studied for use in coronary artery disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Therapy area: Cardiovascular
Developer: Humacyte, Inc. (HUMA)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07730528	Phase 2	Coronary Artery Disease	Not yet recruiting	HUMA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Coronary Artery Disease

More from Humacyte

Acellular Tissue Engineered Vessel FDA approved HAVG Phase 1

Sources

ClinicalTrials.gov NCT07730528

Updated Oct 3, 2026. Something wrong or missing? Report it on the HUMA page.

Follow HUMA, the company behind Humacyte Coronary Tissue Engineered Vessel

See HUMA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

HUMA catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z